Gross Profit Summary of Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.'s latest annual gross profit in 2023 was - USD , down -100.0% from previous year.
Enzon Pharmaceuticals, Inc.'s latest quarterly gross profit in 2024 Q1 was - USD , down 0.0% from previous quarter.
Enzon Pharmaceuticals, Inc. reported a annual gross profit of 26 Thousand USD in annual gross profit 2022, down -96.29% from previous year.
Enzon Pharmaceuticals, Inc. reported a annual gross profit of 701 Thousand USD in annual gross profit 2021, up 1248.08% from previous year.
Enzon Pharmaceuticals, Inc. reported a quarterly gross profit of - USD for 2024 Q1, down 0.0% from previous quarter.
Enzon Pharmaceuticals, Inc. reported a quarterly gross profit of - USD for 2024 Q3, down -100.0% from previous quarter.

Annual Gross Profit Chart of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Historical Annual Gross Profit of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Year	Gross Profit	Gross Profit Growth
2023	- USD	-100.0%
2022	26 Thousand USD	-96.29%
2021	701 Thousand USD	1248.08%
2020	52 Thousand USD	-74.88%
2019	207 Thousand USD	-97.01%
2018	6.91 Million USD	-17.44%
2017	8.37 Million USD	0.02%
2016	8.37 Million USD	-52.01%
2015	17.45 Million USD	-44.0%
2014	31.17 Million USD	-9.63%
2013	34.49 Million USD	10.47%
2012	31.22 Million USD	-33.61%
2011	47.03 Million USD	-47.02%
2010	88.77 Million USD	-35.25%
2009	137.1 Million USD	1.38%
2008	135.23 Million USD	3.53%
2007	130.62 Million USD	-3.62%
2006	135.53 Million USD	0.0%
2005	- USD	-100.0%
2004	122.58 Million USD	3.99%
2003	117.88 Million USD	69.07%
2002	69.72 Million USD	151.51%
2001	27.72 Million USD	128.56%
2000	12.12 Million USD	36.29%
1999	8.9 Million USD	-19.09%
1998	11 Million USD	23.6%
1997	8.9 Million USD	-21.24%
1996	11.3 Million USD	-26.62%
1995	15.4 Million USD	0.0%
1994	15.4 Million USD	55.56%
1993	9.9 Million USD	50.0%
1992	6.6 Million USD	230.0%
1991	2 Million USD	17.65%
1990	1.7 Million USD	0.0%
1989	1.7 Million USD	240.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	26 Thousand USD	0.0%
2024 Q1	- USD	0.0%
2024 Q3	- USD	-100.0%
2023 Q2	- USD	0.0%
2023 Q1	- USD	-100.0%
2023 Q4	- USD	0.0%
2023 Q3	- USD	0.0%
2023 FY	- USD	-100.0%
2022 Q2	- USD	0.0%
2022 Q1	- USD	-100.0%
2022 FY	26 Thousand USD	-96.29%
2022 Q4	26 Thousand USD	0.0%
2022 Q3	- USD	0.0%
2021 Q2	291 Thousand USD	-23.62%
2021 Q1	381 Thousand USD	1020.59%
2021 FY	701 Thousand USD	1248.08%
2021 Q3	- USD	-100.0%
2021 Q4	29 Thousand USD	0.0%
2020 Q3	8000.00 USD	0.0%
2020 Q4	34 Thousand USD	325.0%
2020 FY	52 Thousand USD	-74.88%
2020 Q1	2000.00 USD	-95.92%
2020 Q2	8000.00 USD	300.0%
2019 Q4	49 Thousand USD	2350.0%
2019 Q3	2000.00 USD	-99.03%
2019 FY	207 Thousand USD	-97.01%
2019 Q2	207 Thousand USD	505.88%
2019 Q1	-51 Thousand USD	-124.88%
2018 FY	6.91 Million USD	-17.44%
2018 Q1	15 Thousand USD	15.38%
2018 Q3	-280 Thousand USD	-559.02%
2018 Q2	61 Thousand USD	306.67%
2018 Q4	205 Thousand USD	173.21%
2017 Q2	6.77 Million USD	370.49%
2017 Q3	151 Thousand USD	-97.77%
2017 Q4	13 Thousand USD	-91.39%
2017 FY	8.37 Million USD	0.02%
2017 Q1	1.44 Million USD	68.82%
2016 Q4	853 Thousand USD	-57.05%
2016 FY	8.37 Million USD	-52.01%
2016 Q2	2.27 Million USD	-30.43%
2016 Q3	1.98 Million USD	-12.59%
2016 Q1	3.26 Million USD	3.22%
2015 Q4	3.16 Million USD	-17.58%
2015 Q2	5.19 Million USD	-1.31%
2015 FY	17.45 Million USD	-44.0%
2015 Q3	3.83 Million USD	-26.06%
2015 Q1	5.26 Million USD	-16.07%
2014 Q4	6.26 Million USD	-23.22%
2014 Q1	8.97 Million USD	20.86%
2014 Q2	7.76 Million USD	-13.47%
2014 Q3	8.16 Million USD	5.12%
2014 FY	31.17 Million USD	-9.63%
2013 Q1	10.18 Million USD	1496.84%
2013 Q4	7.42 Million USD	-15.79%
2013 Q3	8.81 Million USD	9.46%
2013 Q2	8.05 Million USD	-20.89%
2013 FY	34.49 Million USD	10.47%
2012 FY	31.22 Million USD	-33.61%
2012 Q4	-729 Thousand USD	-106.58%
2012 Q3	11.07 Million USD	8.52%
2012 Q2	10.2 Million USD	-2.98%
2012 Q1	10.51 Million USD	173.35%
2011 Q4	-14.33 Million USD	-237.97%
2011 Q3	10.39 Million USD	11.0%
2011 Q2	9.36 Million USD	-45.94%
2011 Q1	17.31 Million USD	372.37%
2011 FY	47.03 Million USD	-47.02%
2010 Q1	53.7 Million USD	58.27%
2010 FY	88.77 Million USD	-35.25%
2010 Q2	11.53 Million USD	-78.52%
2010 Q3	11.94 Million USD	3.55%
2010 Q4	3.66 Million USD	-69.31%
2009 Q4	33.93 Million USD	9.3%
2009 Q3	31.04 Million USD	-9.58%
2009 Q2	34.33 Million USD	-8.92%
2009 Q1	37.69 Million USD	8.56%
2009 FY	137.1 Million USD	1.38%
2008 Q4	34.72 Million USD	1.19%
2008 Q3	34.31 Million USD	2.26%
2008 Q1	32.63 Million USD	-3.83%
2008 Q2	33.55 Million USD	2.83%
2008 FY	135.23 Million USD	3.53%
2007 Q4	33.93 Million USD	3.7%
2007 Q2	32.91 Million USD	9.64%
2007 FY	130.62 Million USD	-3.62%
2007 Q3	32.72 Million USD	-0.6%
2007 Q1	30.02 Million USD	-7.29%
2006 FY	135.53 Million USD	0.0%
2006 Q4	32.38 Million USD	-3.94%
2006 Q3	33.71 Million USD	-4.36%
2006 Q2	35.25 Million USD	3.14%
2006 Q1	34.18 Million USD	0.0%
2005 FY	- USD	-100.0%
2005 Q4	- USD	-100.0%
2005 Q3	32.08 Million USD	5.45%
2005 Q2	30.42 Million USD	2.39%
2005 Q1	29.71 Million USD	-2.69%
2004 Q1	31.92 Million USD	6.86%
2004 FY	122.58 Million USD	3.99%
2004 Q3	29.55 Million USD	-4.85%
2004 Q4	30.53 Million USD	3.32%
2004 Q2	31.05 Million USD	-2.7%
2003 Q3	29.73 Million USD	-17.45%
2003 Q2	36.01 Million USD	12.26%
2003 Q1	32.08 Million USD	17.81%
2003 Q4	29.87 Million USD	0.47%
2003 FY	117.88 Million USD	69.07%
2002 Q1	18.46 Million USD	7.71%
2002 Q2	23.36 Million USD	26.49%
2002 Q4	27.23 Million USD	20.75%
2002 Q3	22.55 Million USD	-3.46%
2002 FY	69.72 Million USD	151.51%
2001 Q4	17.14 Million USD	59.46%
2001 FY	27.72 Million USD	128.56%
2001 Q1	8.94 Million USD	73.72%
2001 Q2	9.45 Million USD	5.77%
2001 Q3	10.75 Million USD	13.67%
2000 Q4	5.14 Million USD	23.38%
2000 Q1	4.68 Million USD	56.05%
2000 Q2	2.74 Million USD	-41.46%
2000 Q3	4.17 Million USD	52.24%
2000 FY	12.12 Million USD	36.29%
1999 Q2	2.6 Million USD	44.44%
1999 FY	8.9 Million USD	-19.09%
1999 Q3	1.7 Million USD	-34.62%
1999 Q4	3 Million USD	76.47%
1999 Q1	1.8 Million USD	-35.71%
1998 Q3	1.7 Million USD	-10.53%
1998 FY	11 Million USD	23.6%
1998 Q2	1.9 Million USD	-5.0%
1998 Q4	2.8 Million USD	64.71%
1998 Q1	2 Million USD	-35.48%
1997 Q1	1.4 Million USD	-46.15%
1997 Q2	2.2 Million USD	57.14%
1997 FY	8.9 Million USD	-21.24%
1997 Q4	3.1 Million USD	-24.39%
1997 Q3	4.1 Million USD	86.36%
1996 Q2	3.8 Million USD	65.22%
1996 Q1	2.3 Million USD	-17.86%
1996 Q4	2.6 Million USD	-7.14%
1996 FY	11.3 Million USD	-26.62%
1996 Q3	2.8 Million USD	-26.32%
1995 FY	15.4 Million USD	0.0%
1995 Q3	2.4 Million USD	-50.0%
1995 Q2	4.8 Million USD	9.09%
1995 Q1	4.4 Million USD	69.23%
1995 Q4	2.8 Million USD	16.67%
1994 Q1	8 Million USD	247.83%
1994 Q2	2.5 Million USD	-68.75%
1994 Q3	3.6 Million USD	44.0%
1994 Q4	2.6 Million USD	-27.78%
1994 FY	15.4 Million USD	55.56%
1993 Q4	2.3 Million USD	-11.54%
1993 Q1	2.4 Million USD	209.09%
1993 Q2	2.7 Million USD	12.5%
1993 FY	9.9 Million USD	50.0%
1993 Q3	2.6 Million USD	-3.7%
1992 Q4	-2.2 Million USD	-204.76%
1992 Q1	1.3 Million USD	0.0%
1992 FY	6.6 Million USD	230.0%
1992 Q2	2.8 Million USD	115.38%
1992 Q3	2.1 Million USD	-25.0%
1991 Q3	1.3 Million USD	62.5%
1991 FY	2 Million USD	17.65%
1991 Q1	600 Thousand USD	-25.0%
1991 Q2	800 Thousand USD	33.33%
1991 Q4	1.3 Million USD	0.0%
1990 Q2	600 Thousand USD	0.0%
1990 Q3	100 Thousand USD	-83.33%
1990 Q4	800 Thousand USD	700.0%
1990 Q1	600 Thousand USD	0.0%
1990 FY	1.7 Million USD	0.0%
1989 Q3	600 Thousand USD	200.0%
1989 Q4	600 Thousand USD	0.0%
1989 Q2	200 Thousand USD	-60.0%
1989 Q1	500 Thousand USD	-37.5%
1989 FY	1.7 Million USD	240.0%

Peer Gross Profit Comparison of Enzon Pharmaceuticals, Inc.

Name	Gross Profit	Gross Profit Difference
Burzynski Research Institute, Inc.	- USD	NaN%
Arch Therapeutics, Inc.	-2439.00 USD	100.0%
Evofem Biosciences, Inc.	11.7 Million USD	100.0%
Nascent Biotech, Inc.	-319.5 Thousand USD	100.0%
Rebus Holdings, Inc.	- USD	NaN%
Santhera Pharmaceuticals Holding AG	119.1 Million USD	100.0%
Qrons Inc.	- USD	NaN%
Adynxx, Inc.	- USD	NaN%
Neon Bloom, Inc.	- USD	NaN%
Northwest Biotherapeutics, Inc.	-25.79 Million USD	100.0%
ProtoKinetix, Incorporated	-48.25 Thousand USD	100.0%
Skye Bioscience, Inc.	-124.25 Thousand USD	100.0%
Eiger BioPharmaceuticals, Inc.	14.99 Million USD	100.0%
Nanobac Pharmaceuticals, Incorporated	3102.00 USD	100.0%
Institute of Biomedical Research Corp.	- USD	NaN%
SQZ Biotechnologies Company	9.79 Million USD	100.0%
Intellipharmaceutics International Inc.	65.72 Thousand USD	100.0%
Propanc Biopharma, Inc.	-34.15 Thousand USD	100.0%
Mesoblast Limited	-35.16 Million USD	100.0%
Marizyme, Inc.	457.7 Thousand USD	100.0%
Genus plc	178.7 Million USD	100.0%
VioQuest Pharmaceuticals, Inc.	- USD	NaN%
Pharming Group N.V.	220.1 Million USD	100.0%
Therapeutic Solutions International, Inc.	62.22 Thousand USD	100.0%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	100.0%
Nymox Pharmaceutical Corporation	-11 Thousand USD	100.0%
ContraFect Corporation	-154 Thousand USD	100.0%
PsyBio Therapeutics Corp.	-50 Thousand USD	100.0%
Sienna Biopharmaceuticals, Inc.	- USD	NaN%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	100.0%
IMV Inc.	-962.29 Thousand USD	100.0%
AXIM Biotechnologies, Inc.	-387.5 Thousand USD	100.0%
MultiCell Technologies, Inc.	49.32 USD	100.0%
ONE Bio Corp.	20.12 Million USD	100.0%
Accustem Sciences Inc.	- USD	NaN%
RVL Pharmaceuticals plc	40.26 Million USD	100.0%
Arno Therapeutics, Inc.	- USD	NaN%
EV Biologics, Inc.	48.9 Thousand USD	100.0%
Q BioMed Inc.	-8988.00 USD	100.0%
Emmaus Life Sciences, Inc.	28.25 Million USD	100.0%
Mosaic ImmunoEngineering Inc.	- USD	NaN%
Biomind Labs Inc.	-15.42 Thousand USD	100.0%
American Oriental Bioengineering, Inc.	44.35 Million USD	100.0%
Provectus Biopharmaceuticals, Inc.	-1.14 Million USD	100.0%
TetraLogic Pharmaceuticals Corporation	- USD	NaN%
Oncotelic Therapeutics, Inc.	70 Thousand USD	100.0%
GlobeStar Therapeutics Corporation	- USD	NaN%
THC Farmaceuticals, Inc.	-4952.00 USD	100.0%
Acro Biomedical Co., Ltd.	140.5 Thousand USD	100.0%
Curative Biotechnology, Inc.	-97.51 Thousand USD	100.0%
GB Sciences, Inc.	-624.00 USD	100.0%
Alpha Cognition Inc.	-86.02 Thousand USD	100.0%
HST Global, Inc.	- USD	NaN%
CSL Limited	7.56 Billion USD	100.0%
Wesana Health Holdings Inc.	- USD	NaN%
Halberd Corporation	-208.00 USD	100.0%
Enzolytics Inc.	30.7 Thousand USD	100.0%
Agentix Corp.	- USD	NaN%
Resverlogix Corp.	- USD	NaN%
Nuo Therapeutics, Inc.	482.43 Thousand USD	100.0%
MetaStat, Inc.	- USD	NaN%
argenx SE	1.1 Billion USD	100.0%
Endonovo Therapeutics, Inc.	-514.51 Thousand USD	100.0%
RespireRx Pharmaceuticals Inc.	- USD	NaN%
GeneThera, Inc.	- USD	NaN%
Inhibitor Therapeutics, Inc.	- USD	NaN%
AVAX Technologies, Inc.	617.38 Thousand USD	100.0%
Zenith Capital Corp.	- USD	NaN%
Genscript Biotech Corporation	409.55 Million USD	100.0%
Ember Therapeutics, Inc.	- USD	NaN%
Anthera Pharmaceuticals, Inc.	- USD	NaN%
Sigyn Therapeutics, Inc.	-8856.00 USD	100.0%
WPD Pharmaceuticals Inc.	- USD	NaN%
Cotinga Pharmaceuticals Inc.	-83.84 Thousand USD	100.0%
Kadimastem Ltd	-630.13 Thousand USD	100.0%
Helix BioMedix, Inc.	987.98 Thousand USD	100.0%
VitaSpring Biomedical Co. Ltd.	- USD	NaN%
Capstone Therapeutics Corp.	9.61 Million USD	100.0%
BioStem Technologies, Inc.	15.42 Million USD	100.0%
Oncology Pharma Inc.	- USD	NaN%
Reve Technologies, Inc.	- USD	NaN%
LadRx Corporation	-11.83 Thousand USD	100.0%
Cell Source, Inc.	- USD	NaN%
Regen BioPharma, Inc.	176.56 Thousand USD	100.0%
Regen BioPharma, Inc.	176.56 Thousand USD	100.0%
NovAccess Global Inc.	- USD	NaN%
Affymax, Inc.	1.35 Million USD	100.0%
Itoco Inc.	- USD	NaN%
Rasna Therapeutics, Inc.	- USD	NaN%
Pathfinder Cell Therapy, Inc.	- USD	NaN%
Mobile Lads Corp.	- USD	NaN%
CytoDyn Inc.	-29 Thousand USD	100.0%
Claritas Pharmaceuticals, Inc.	- USD	NaN%
NDT Pharmaceuticals Inc.	- USD	NaN%
NanoSphere Health Sciences Inc.	- USD	NaN%
Alseres Pharmaceuticals, Inc.	450.04 Thousand USD	100.0%
SYBLEU INC	11.69 Thousand USD	100.0%
Advanced Proteome Therapeutics Corporation	- USD	NaN%
ImmunoCellular Therapeutics, Ltd.	- USD	NaN%
International Stem Cell Corporation	4.6 Million USD	100.0%
Bioxytran, Inc.	-8285.00 USD	100.0%
GlobeImmune, Inc.	- USD	NaN%
Predictive Technology Group, Inc.	- USD	NaN%
ProText Mobility, Inc.	- USD	NaN%
Cardax, Inc.	- USD	NaN%
VG Life Sciences Inc.	- USD	NaN%
Kaleido Biosciences, Inc.	- USD	NaN%
Advaxis, Inc.	- USD	NaN%
Adhera Therapeutics, Inc.	- USD	NaN%
RenovaCare, Inc.	- USD	NaN%
Regnum Corp.	- USD	NaN%
Innovation Pharmaceuticals Inc.	-373 Thousand USD	100.0%
Neutra Corp.	14.33 Thousand USD	100.0%
Windtree Therapeutics, Inc.	-82 Thousand USD	100.0%
PureTech Health plc	-1.6 Million USD	100.0%
Coeptis Therapeutics, Inc.	-1 Million USD	100.0%
IXICO plc	3.27 Million USD	100.0%
IntelGenx Technologies Corp.	-694 Thousand USD	100.0%
Gelesis Holdings, Inc.	-1.79 Million USD	100.0%
CSL Limited	7.7 Billion USD	100.0%
Cellectis S.A.	18 Thousand USD	100.0%

Global Stocks Search

Enzon Pharmaceuticals, Inc. (ENZN)

Gross Profit Summary of Enzon Pharmaceuticals, Inc.

Annual Gross Profit Chart of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Historical Annual Gross Profit of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Peer Gross Profit Comparison of Enzon Pharmaceuticals, Inc.